The U.S. Food and Drug Administration opened submissions for its PreCheck program, inviting drugmakers to apply for a pathway intended to accelerate construction of domestic drug manufacturing sites. The initiative aims to reduce regulatory friction and shorten timelines for bringing new or expanded facilities online in the U.S. The PreCheck window offers manufacturers an opportunity to align project plans with FDA expectations earlier in the process—potentially shaving time from approvals and inspections. Companies pursuing reshoring and capacity expansion are likely to view PreCheck as a lever to de‑risk capital deployment and support supply‑chain resilience.